Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 2968025, 10 pages
https://doi.org/10.1155/2018/2968025
Review Article

The Therapeutic Effects of a Traditional Chinese Medicine Formula Wuzi Yanzong Pill for the Treatment of Oligoasthenozoospermia: A Meta-Analysis of Randomized Controlled Trials

1Department of Obstetrics and Gynecology, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong
2Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Sha Tin, Hong Kong
3School of Chinese Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong
4Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong

Correspondence should be addressed to David Yiu Leung Chan; kh.ude.khuc@61lycdrd

Received 9 August 2017; Accepted 18 December 2017; Published 17 January 2018

Academic Editor: Kazim Sahin

Copyright © 2018 Ming Peng Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Oligoasthenozoospermia is a crucial factor in male infertility. Wuzi Yanzong (WZYZ) pill is a popular traditional Chinese medicine (TCM) formula which has been used for male infertility treatment for years. However, its effects on semen quality remain controversial. We conducted a preregistered meta-analysis to assess the effect of WZYZ pill for the therapeutic effects on oligoasthenozoospermia. Five randomized controlled trials including 960 participants were selected from databases of domains in North-East Asian regions, PubMed, Embase, and Cochrane Library. WZYZ pill group yielded a greater mean increment on sperm concentration (5 trials: MD 5.99, 95% CI 2.12–9.85, ), sperm motility (5 trials: MD 4.57, 95% CI 0.47–8.68, ), sperm morphology (2 trials: MD −1.93, 95% CI −4.87–1.01, ), activity of acrosomal enzyme (2 trials: MD 28.27, 95% CI 12.41–44.14, ), volume of semen (2 trials: MD 0.56, 95% CI 0.21–0.91, ), and a decrement of sperm DNA fragmentation index (2 trials: MD −3.82, 95% CI −6.45–−1.19, ). However, qualities of selected studies were generally unsatisfactory, and there was inherent heterogeneity among some of the outcomes. Despite these limitations, the WZYZ pill improved sperm quality by improving several semen parameters and decreasing DNA damage in oligoasthenozoospermia patients.